Management

show all hide all

PTI’s management team has many years of drug development experience. Prior to coming together we have successfully put over 25 drugs through the approval process. Our expertise represents a cross-section of drug development disciplines, including preclinical development, clinical development, medical affairs, regulatory, pharmaceutical development and supply chain management.

Remi Barbier

Chairman of the Board, President & CEO

Remi Barbier has served as PTI's President and Chief Executive Officer since he founded the Company in 1998. Prior to PTI, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company; ArQule, a chemistry company; and EnzyMed (now owned by Albany Molecular Research), a chemistry company. Prior to PTI Mr. Barbier served as Chief Operating Officer of Exelixis. Prior to that, he was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company. Mr. Barbier received his undergraduate degree from Oberlin College and his graduate degree from the University of Chicago.

Nadav Friedmann PhD, MD

Chief Medical & Operating Officer

Dr. Nadav Friedmann joined PTI as Chief Medical and Operating Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various leadership positions, with Johnson & Johnson, a healthcare company, including Vice President and Head of Research of J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann is a graduate of Albert Einstein College of Medicine, where he received an MD, and of the University of California, San Diego, where he received a PhD degree in Biochemistry.

Peter S. Roddy

VP & Chief Financial Officer

Peter Roddy has served as Chief Financial Officer since November 2002. From 1990 to 2002, Mr. Roddy held a variety of senior management positions at COR Therapeutics, Inc. (now Millennium Pharmaceuticals, Inc.) a biopharmaceutical company, including Senior Vice President, Finance and Chief Financial Officer between 2000 and 2002. Prior to 1990, Mr. Roddy held a variety of positions at Price Waterhouse & Company, Hewlett Packard Company and MCM Laboratories, Inc. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.

Grant L. Schoenhard PhD

Chief Scientific Officer

Dr. Schoenhard serves as PTI's Chief Scientific Officer, a promotion from his previous position with the Company as Vice President of Preclinical Development. Prior to joining PTI, Dr. Schoenhard was Sr. Director of Pharmacokinetics, Drug Metabolism and Pharmacology at Genentech, Inc. From 1974 to 1998, Dr. Schoenhard also held various management positions at Searle, a pharmaceutical company of Monsanto Corp., including Executive Director of Pharmacokinetics, Drug Metabolism and Radiochemistry. He is also Adjunct Professor of Pharmacology, School of Medicine, University of Pennsylvania. Dr. Schoenhard received his BS from Michigan State University and his MS and PhD from Oregon State University.

Michael Zamloot

Sr. VP, Technical Operations

Michael Zamloot serves as Senior Vice President of Technical Operations. Prior to PTI, Mr. Zamloot was Director of technical services and strategic sourcing functions at Athena Neurosciences, Inc. for 6 years. Prior to that, Mr. Zamloot held staff and management positions in pharmaceutical development for several multinational firms including Boehringer Mannheim, Boehringer Ingelheim Pharmaceutical and Ciba-Geigy Pharmaceuticals. Mr. Zamloot holds a BS in Chemical Engineering, with honors, from New Jersey Institute of Technology.

George Ben Thornton PhD

Sr. VP, Technology

George "Ben" Thornton, Ph.D. serves as Vice President of Technology. Prior to PTI, Dr. Thornton spent nine years at Apovia AG (Munich, Germany) as Head of Research and a Member of the Managing Board (Vorstand F&E), and Managing Director of Apovia Inc.(San Diego). Prior to that, Dr. Thornton was the Vice President of Preclinical Development at GeneMedicine. Dr. Thornton was the Director of Research of the Pharmaceutical Research Institute (responsible for research centers in La Jolla, CA and Sydney, Australia). Dr. Thornton received his undergraduate degree from Abilene Christian University and his Ph.D. from the University of Texas Graduate School of Biomedical Sciences (Houston). He was a post-doctoral fellow at the Roche Institute of Molecular Biology.

Peter Butera

VP, Clinical Operations

Peter Butera serves as Vice President, Clinical Operations. Prior to PTI, Mr. Butera was Director, Clinical Operations at IntraBiotics Pharmaceuticals, Inc. Prior to that Mr. Butera held clinical research management positions at PharmaNet, Inc. and Covance, Inc., two contract drug development services companies, and staff positions at AstraZeneca. Mr. Butera holds a BS in Biology from St. Joseph's University.

Michael Marsman Pharm.D

VP, Regulatory Affairs

Michael Marsman, Pharm.D. serves as Vice President, Regulatory Affairs. Prior to PTI, Dr. Marsman was Vice President, Cardiovascular Regulatory Affairs at Millennium Pharmaceuticals, Inc. Prior to that, Dr. Marsman held management positions in regulatory affairs at COR Therapeutics, Inc. (now Millennium Pharmaceuticals, Inc.) Sequus Pharmaceuticals, Inc. and Syntex Pharmaceuticals (now Syntex/Roche). Dr. Marsman received his B.A. from the University of California, Davis and his Pharm.D. from University of the Pacific.

Roger Fu Ph.D

VP, Pharmaceutical Development

Roger Fu, Ph.D. serves as Vice President, Pharmaceutical Development. Prior to PTI, Dr. Fu spent five years at IntraBiotics, most recently as Director, Formulation Development and Manufacturing. Prior to that, Dr. Fu spent 16 years at Syntex/Roche where he held various senior staff research positions. Dr. Fu is the formulation inventor of Syntex/Roche's immune suppressive drug, Cellcept IV and an ophthalmic product, Acular. Cellcept IV and Acular are currently on the market. Dr. Fu received his undergraduate degree from National Taiwan University and his Ph.D. from University of California, San Francisco.